Drug Trial Radar · NCT06090721
DMT310-009 Topical in the Treatment of Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
520
Actual
Start
Dec 8, 2023
Primary completion
Mar 31, 2025
Study completion Apr 30, 2025
Sponsor
- Lead sponsor
- Dermata TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris
Conditions
- Acne Vulgaris
Interventions
DMT310Drug
Topical Powder
PlaceboDrug
Placebo Topical Powder
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy as measured by lesion countsTime frame: 12 weeks
- Efficacy as measured by Investigator Global Assessment (IGA)Time frame: 12 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Center for Dermatology Clinical Research, Inc.
Freemont, California
DermResearch
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.